Skip to Content

Weekly Drug News Round Up - May 6, 2015

FDA Approves Tuzistra XR

Vernalis and Tris Pharma Receive FDA Approval for Tuzistra XR Read More…

Cough can be a symptom of a variety of conditions. This past week, the U.S. Food and Drug Administration (FDA) approved Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), an extended-release (XR) opiate agonist cough suppressant and histamine-1 (H1) receptor antagonist antihistamine combination used for the relief of cough and symptoms associated with upper respiratory allergies or the common cold. Tuzistra XR oral suspension is dosed every 12 hours in adults. Tuzistra XR is the only codeine based extended-release oral suspension cough-cold treatment in the U.S. Tussionex, another popular extended-release cough-cold suspension in the U.S, is a combination of chlorpheniramine and hydrocodone.

FDA Approves Raplixa To Control Surgical Bleeding

Raplixa is used to help control bleeding when standard surgical techniques, such as suture, ligature or cautery, aren’t the best option Read More…

The U.S. Food and Drug Administration (FDA) has approved The Medicines Company’s Raplixa (fibrin sealant [human]), the first spray-dried fibrin sealant approved by the agency. It is used to help control bleeding during surgery. Raplixa, a biological product, contains fibrinogen and thrombin, two proteins found in human plasma, the liquid portion of blood. Raplixa can be sprayed with a delivery device onto a bleeding site, and is approved for use in conjunction with an absorbable gelatin sponge. The most commonly reported adverse reactions were surgical pain, nausea, constipation, fever and decreased blood pressure.

Digoxin Use in Heart Problems: Study

Patients taking digoxin should not alter their medications without first speaking to their physician Read More...

Digoxin has been is use for decades to treat heart problems, but dosing is tricky and blood tests are needed to keep blood levels steady. In a review of 19 studies, researchers looked at the connection between digoxin use and premature death. Among patients with the irregular heart rhythm known as atrial fibrillation, researchers found a 29 percent greater risk of premature death, while the increased risk was 14 percent among heart failure patients. However, the study does not prove a relationship between higher risk of premature death and digoxin, only that an association exists.

Nitrofurantoin Effectiveness for UTIs Questioned: Study

In many clinic settings, nitrofurantoin is the most common antibiotic prescribed for a urinary tract infection (UTI) Read More...

A recent study published in the Canadian Medical Journal evaluated over 10,000 older women with reduced kidney function and 180,000 women with normal kidney function. Researchers found that nitrofurantoin was less successful than other drugs in treating UTIs among all women in the study - not just those with reduced kidney function. Additionally, results suggest nitrofurantoin use may boost the odds that another round of antibiotics or hospitalization may be needed. Ciprofloxacin (Cipro) is commonly used for UTIs, but may be linked with greater side effects and increasing antibiotic resistance.

12 Things to Know About Lyrica: Slideshow

Lyrica is a medication that wears many hats, but do you know what you really need to know about this treatment? Read More…

Lyrica (pregabalin) was first FDA-approved in 2004 for epilepsy and seizures. Since that time, many other uses have been studied for Lyrica. From the aches of fibromyalgia to the nerve pain from shingles, Lyrica is used daily by millions for effective pain control. However, Lyrica side effects can hamper treatment, so it’s important to know the drug, what dose ranges make sense, and what common side effects to expect. Knowledge in healthcare is a powerful tool to stay safe when it comes to medication therapy, so follow along with the Drugs.com slideshow to learn more about Lyrica.